Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

Article  PubMed  Google Scholar 

Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Kollermann J. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int. 2010;106(1):37–43.

Article  PubMed  Google Scholar 

Huo H, Shen S, He D, Liu B, Yang F. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies. Prostate Cancer Prostatic Dis. 2023;26(1):16–24.

Article  CAS  PubMed  Google Scholar 

Alberts I, Prenosil G, Sachpekidis C, et al. Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. Eur J Nucl Med Mol Imaging. 2020;47(3):614–23.

Article  CAS  PubMed  Google Scholar 

Van den Broeck T, van den Bergh RCN, Briers E, et al. Biochemical recurrence in prostate cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus. 2020;6(2):231–4.

Article  PubMed  Google Scholar 

Hohberg M, Kobe C, Täger P, et al. Combined early and late 68Ga-PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA Levels. Mol Imaging Biol. 2019;21:558–66.

Article  CAS  PubMed  Google Scholar 

Kunikowska J, Pełka K, Tayara O, Królicki L. 68Ga-PSMA-11 PET/CT in patients with biochemical recurrence of prostate cancer after primary treatment with curative intent-impact of delayed imaging. J Clin Med. 2022;11(12):3311.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu Y, Wilson ZJ, Xu G, Xu Z, Pan T, Wei P. Diagnostic performance of PSMA-based 18 F-DCFPyL PET/CT in prostate cancer patients after definitive treatment with PSA level ≤0.2 ng/mL. Clin Nucl Med. 2023;48(12):1021–7.

Article  PubMed  Google Scholar 

Solomonidou N, Germanou D, Strouthos I, et al. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. Eur J Nucl Med Mol Imaging. 2023;50(8):2529–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Witkowska-Patena E, Giżewska A, Dziuk M, Miśko J, Budzyńska A, Walęcka-Mazur A. Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml. Prostate Cancer Prostatic Dis. 2020;23(2):343–8.

Article  CAS  PubMed  Google Scholar 

Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci USA. 2020;117(5):2265–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Chen Z, Zhu Y, et al. Total-body [68 Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50(13):4096–106.

Article  CAS  PubMed  Google Scholar 

Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59(3):469–78.

Article  PubMed  Google Scholar 

Mihatsch PW, Beissert M, Pomper MG, et al. Changing threshold-based segmentation has no relevant impact on semi-quantification in the context of structured reporting for PSMA-PET/CT. Cancers (Basel). 2022;14(2):270.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Sluis J, Boellaard R, Somasundaram A, et al. Image quality and semiquantitative measurements on the biograph vision PET/CT system: initial experiences and comparison with the biograph mCT. J Nucl Med. 2020;61(1):129–35.

Article  PubMed  Google Scholar 

Calderón E, Schmidt FP, Lan W, et al. Image quality and quantitative PET parameters of low-dose [18F]FDG PET in a long axial field-of-view PET/CT scanner. Diagnostics (Basel). 2023;13(20):3240.

Article  PubMed  Google Scholar 

Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–63.

Article  PubMed  PubMed Central  Google Scholar 

Alberts I, Sachpekidis C, Gourni E, et al. Dynamic patterns of 68Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2020;47(1):160–7.

Article  PubMed  Google Scholar 

Badawi RD, Shi H, Hu P, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60(3):299–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466–86.

Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403–17.

Article  PubMed  Google Scholar 

Afshar-Oromieh A, da Cunha ML, Wagner J, et al. Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021;48(9):2925–34.

Article  PubMed  PubMed Central  Google Scholar 

Burgard C, Hoffmann MA, Frei M, et al. Detection efficacy of 68Ga-PSMA-11 PET/CT in biochemical recurrence of prostate cancer with very low PSA levels: a 7-year, two-center “real-world” experience. Cancers (Basel). 2023;15(5):1376.

Article  CAS  PubMed  Google Scholar 

Deek MP, Van der Eecken K, Sutera P, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40(29):3377–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jadvar H, Abreu AL, Ballas LK, Quinn DI. Oligometastatic prostate cancer: current status and future challenges. J Nucl Med. 2022;63(11):1628–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dietlein F, Kobe C, Neubauer S, et al. PSA-stratified performance of 18F- and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017;58(6):947–52.

Article  CAS  PubMed  Google Scholar 

Dietlein F, Kobe C, Hohberg M, et al. Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer. J Nucl Med. 2020;61(5):729–34.

Article  CAS  PubMed  Google Scholar 

Rauscher I, Krönke M, König M, et al. Matched-pair comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61(1):51–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44(6):941–9.

Article  CAS  PubMed  Google Scholar 

Demirci E, Kabasakal L, Şahin OE, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40(1):86–91.

Article  PubMed  Google Scholar 

Rahbar K, Weckesser M, Huss S, et al. Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016;57(4):563–7.